ImmunityBio Strengthens Balance Sheet Amid Regulatory Scrutiny and Growth Push

ImmunityBio executes a dual financial strategy, converting debt and securing new funding, as its cancer drug ANKTIVA sees 700% revenue growth but faces an FDA warning letter.

ImmunityBio is executing a significant financial restructuring during a period of heightened regulatory attention. The company is addressing recent challenges, including an FDA warning letter and related lawsuits, by simultaneously reducing debt and securing new capital, signaling a strategic pivot toward financial stability and continued expansion.

Operational Momentum and Regulatory Hurdles

On the operational front, business is advancing robustly. The company's core product, ANKTIVA, has now gained regulatory approval in 34 countries across five major regulatory zones, including the European Union, the United Kingdom, Saudi Arabia, and Macau. This global footprint underpinned a dramatic surge in net revenue for 2025, which reached $113 million—representing a 700% increase compared to the prior year.

This growth push, however, has been accompanied by regulatory friction. On March 24, the U.S. Food and Drug Administration issued a warning letter concerning promotional materials for ANKTIVA. The agency took issue with claims made in a television advertisement and a podcast that suggested the therapy could treat all types of cancer and function as a single-injection treatment. The subsequent decline in the company's share price erased nearly $2 billion in market capitalization, according to statements from law firms including Hagens Berman and Block & Leviton. Both firms are now investigating potential class action lawsuits for alleged violations of securities laws.

Looking ahead, ImmunityBio plans to submit a supplemental Biologics License Application in the fourth quarter of 2026 for the treatment of papillary disease. Patient recruitment for the pivotal QUILT-2.005 study is complete, and an independent data monitoring committee has confirmed the trial is statistically powered to demonstrate clinically meaningful differences between ANKTIVA plus BCG and BCG alone.

A Dual-Pronged Financial Strategy

The company's recent financial maneuvers are a direct response to this complex backdrop. In a key transaction on March 31, Dr. Patrick Soon-Shiong, the firm's founder and Executive Chairman, converted $25 million of an outstanding promissory note into 4.6 million new shares of ImmunityBio stock through his holding company, Nant Capital. This conversion reduces the principal debt from the original $505 million note issued in December 2024 to approximately $480 million.

Concurrently, ImmunityBio secured an additional $75 million in cash under its existing Revenue Interest Purchase Agreement with Oberland Capital. This infusion raises the total committed capital from Oberland to $375 million. The agreement's terms stipulate that Oberland will receive a revenue interest ranging from 5.625% to 12.50% of net sales. This structure remains in place until Oberland has recouped 195% of its cumulative investment. Should payments reach the $375 million threshold by 2029, the revenue interest rate will drop to a fixed 2.8125%.